Reshma Kewalramani insider trades

Open-market stock purchases and sales by Reshma Kewalramani, CEO & President at Vertex Pharmaceuticals Inc / MA, from SEC Form 4 filings since Oct 8, 2018.

Track record: 100% of 4 scored buys are up 5% or more since purchase, averaging +98%.

Recent trades

DateStockTradeValue
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$192K
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$57.8K
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$116K
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$1.2M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$1.6M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$1.7M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$7.7M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$225K
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$1.3M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$466K
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$1.2M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$3M
Feb 27, 2026VRTX Vertex Pharmaceuticals Inc / MASold$857K
Feb 24, 2026VRTX Vertex Pharmaceuticals Inc / MASold (not open market)$2.4M
Feb 17, 2026VRTX Vertex Pharmaceuticals Inc / MABought (not open market)—
Feb 17, 2026VRTX Vertex Pharmaceuticals Inc / MASold (not open market)$3.2M
Feb 13, 2026VRTX Vertex Pharmaceuticals Inc / MASold (not open market)$6.4M
Feb 10, 2026VRTX Vertex Pharmaceuticals Inc / MASold (not open market)$3.9M
Jan 22, 2026VRTX Vertex Pharmaceuticals Inc / MABought (not open market)—
Jan 22, 2026VRTX Vertex Pharmaceuticals Inc / MABought (not open market)—

Companies traded

  • VRTX Vertex Pharmaceuticals Inc / MA: 4 buys, 70 sales, last Feb 27, 2026
  • DNA Ginkgo Bioworks Holdings, Inc: other filings, last Jun 12, 2024

Get free alerts when Reshma Kewalramani files a new trade →